OMNIAB INC
OABI · NASDAQ
Updated at 2026-10-14 08:52:42
- Today's High
- $4.81
- Today’s Low
- $4.62
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $4.77
- Previous Close
- $4.77
- Volume
- 988.62K
- Market Cap
- $693.51M
- P/E Ratio
- --
- EPS
- $-0.36
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Life Sciences Tools & Services
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 5980 HORTON STREET, EMERYVILLE, CA, UNITED STATES, 94608
- Country
- US
- Listing Date
- 2020-10-09
- Fiscal Year End
- December
- Shares Outstanding
- 144.97M
- CIK
- 0001846253
- Website
- www.omniab.com
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Financial Metrics
Revenue
2026-06-30
$13.41M
2026-03-31
$14.4M
2025-12-31
$8.37M
2025-09-30
$2.23M
Operating Expenses
2026-06-30
$19.44M
2026-03-31
$16.3M
2025-12-31
$16.3M
2025-09-30
$15.71M
Net Income
2026-06-30
-$5.85M
2026-03-31
-$7.7M
2025-12-31
-$14.17M
2025-09-30
-$16.52M
Net Profit Margin
2026-06-30
-43.67%
2026-03-31
-53.47%
2025-12-31
-169.28%
2025-09-30
-738.05%
Earnings Per Share
2026-06-30
$-0.05
2026-03-31
$-0.06
2025-12-31
$-0.11
2025-09-30
$-0.14
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$1.99M
2026-03-31
-$486K
2025-12-31
-$6.83M
2025-09-30
-$10.7M
Effective Tax Rate
2026-06-30
5.68%
2026-03-31
--
2025-12-31
2.52%
2025-09-30
-7.55%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $13.41M | $14.4M | $8.37M | $2.23M |
| Operating Expenses | $19.44M | $16.3M | $16.3M | $15.71M |
| Net Income | -$5.85M | -$7.7M | -$14.17M | -$16.52M |
| Net Profit Margin | -43.67% | -53.47% | -169.28% | -738.05% |
| Earnings Per Share | $-0.05 | $-0.06 | $-0.11 | $-0.14 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$1.99M | -$486K | -$6.83M | -$10.7M |
| Effective Tax Rate | 5.68% | -- | 2.52% | -7.55% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.